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Abstract  
Malaria is a parasitic disease impacting 3 billion 
people worldwide. The Plasmodium falciparum 
is drug resistant to 90% of antimalarial 
compounds. Artemisinin is being used in a 
variety of forms to treat Malaria, and the best 
way is in edible tablets created from organic 
Artemisia annua.  
Project Goals/Objectives 
Determine the ideal treatment for malaria derived 
from the A. annua by analyzing the benefits and 
costs of ACTs, pACT and transgenic A. annua. 
 
 
Why Malaria? 
Results and Discussion  
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Measures for Attribution  
Analyze mortality rates and incidence rates of 
malaria recorded by the WHO. Analyze the 
economic impact on a country based on GDP. 
Analyze if socially acceptable by people by 
studying compliance.  
Injects the Plasmodium 
falciparum parasite (1)  
 
 
 
 
Description of Treatments 
 
Artemisia annua Glandular trichomes  
Artemisinin is produced in the 
glandular trichomes of the A. annua. 
• pACT= best treatment option 
• Clonally propagated yields 1.4% Artemisinin 
content consistently (4) 
• Least likely for drug resistance  
• Already accepted in developing countries 
• $0.10-$0.30/ treatment (4) 
• Production occurs in developing country 
• Method shown below  
 
 
• Endangers 3 billion people 
     worldwide  
• 90% cases in Africa(2) 
• 10% reduction of GDP (1) 
 
 
ACT= Artemisinin Combination Therapy, 
produced in bacterial plasmids or extracted from 
A. annua, combined  with other antimalarials 
pACT= Organic A. annua, edible tablet created 
from plant leaves 
Transgenic= Metabolically engineered A. annua, 
also edible tablet created from  plant leaves 
 
Analysis of Treatments  
Sustainability 
 Effectiveness Resistance 
Artemisinin 
Content 
 
• Transgenic produces 7.65 times the amount of AN produced 
in pACT (3) 
• ACT resistance rapidly compared to pACT (4) 
Public 
Acceptance  
WHO 
Approval  
Delivery to 
Body  
Social Acceptability 
 
• WHO approves ACTs (5) 
• pACTs already widely accepted in developing countries (4) 
 
Cost 
Production 
Location 
Production 
Method 
Economic Feasibility 
• pACT cost $0.10- $0.30 / treatment (4) 
• ACT costs $6 / treatment (6) 
• pACT production could occur in developing country (4)   
• ACT production is costly and nondomestic  (6)  
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